Literature DB >> 2370329

Screening and surveillance of patients at high risk for malignant melanoma result in detection of earlier disease.

G D Masri1, W H Clark, D Guerry, A Halpern, C J Thompson, D E Elder.   

Abstract

Screening, surveillance, and educational programs have been recommended for members of hereditary melanoma kindreds with dysplastic nevi, who are at very high risk for melanoma. For melanomas detected in a surveillance program offered to 555 such persons, the average thickness was 0.52 mm for 28 surveillance incident melanomas, 0.55 mm for 64 nonsurveillance incident melanomas, and 1.44 mm for 48 index lesions (p less than 0.001). The proportion of cases with level I or II invasion was 60.8%, 58.3%, and 36.2% respectively (p = 0.002). The nonsurveillance incident melanomas were diagnosed before entry into the surveillance program, but these patients were presumably aware of the earlier occurrence of two index melanomas in their families. These findings are consistent with a favorable effect of surveillance and education in a high-risk population and suggest that patient factors as well as physician factors may contribute to early diagnosis.

Entities:  

Mesh:

Year:  1990        PMID: 2370329     DOI: 10.1016/0190-9622(90)70149-c

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  16 in total

1.  Curable melanomas: seek, and ye shall find.

Authors:  D Guerry; A C Halpern
Journal:  J Gen Intern Med       Date:  1992 Mar-Apr       Impact factor: 5.128

Review 2.  The detection and management of dysplastic nevi and early melanoma.

Authors:  J K Rivers
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

Review 3.  Strategies for early melanoma detection: Approaches to the patient with nevi.

Authors:  Agnessa Gadeliya Goodson; Douglas Grossman
Journal:  J Am Acad Dermatol       Date:  2009-05       Impact factor: 11.527

Review 4.  Skin cancer-related prevention and screening behaviors: a review of the literature.

Authors:  Nadine A Kasparian; Jordana K McLoone; Bettina Meiser
Journal:  J Behav Med       Date:  2009-06-12

5.  Effectiveness and causes for failure of surveillance of CDKN2A-mutated melanoma families.

Authors:  Jasper I van der Rhee; Femke A de Snoo; Hans F A Vasen; Wolter J Mooi; Hein Putter; Nelleke A Gruis; Nicole A Kukutsch; Wilma Bergman
Journal:  J Am Acad Dermatol       Date:  2011-05-12       Impact factor: 11.527

6.  The dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspects.

Authors:  Keith Duffy; Douglas Grossman
Journal:  J Am Acad Dermatol       Date:  2012-07       Impact factor: 11.527

Review 7.  Melanoma risk factors and atypical moles.

Authors:  M L Williams; R W Sagebiel
Journal:  West J Med       Date:  1994-04

8.  Use of host factors to identify people at high risk for cutaneous malignant melanoma .

Authors:  L D Marrett; W D King; S D Walter; L From
Journal:  CMAJ       Date:  1992-08-15       Impact factor: 8.262

Review 9.  Li-Fraumeni syndrome: cancer risk assessment and clinical management.

Authors:  Kate A McBride; Mandy L Ballinger; Emma Killick; Judy Kirk; Martin H N Tattersall; Rosalind A Eeles; David M Thomas; Gillian Mitchell
Journal:  Nat Rev Clin Oncol       Date:  2014-03-18       Impact factor: 66.675

10.  Skin examination behavior: the role of melanoma history, skin type, psychosocial factors, and region of residence in determining clinical and self-conducted skin examination.

Authors:  Nadine A Kasparian; Richard Bränström; Yu-mei Chang; Paul Affleck; Lisa G Aspinwall; Aad Tibben; Esther Azizi; Orna Baron-Epel; Linda Battistuzzi; William Bruno; May Chan; Francisco Cuellar; Tadeusz Debniak; Dace Pjanova; Slawomir Ertmanski; Adina Figl; Melinda Gonzalez; Nicholas K Hayward; Marko Hocevar; Peter A Kanetsky; Sancy Leachman; Wilma Bergman; Olita Heisele; Jane Palmer; Barbara Peric; Susana Puig; Dirk Schadendorf; Nelleke A Gruis; Julia Newton-Bishop; Yvonne Brandberg
Journal:  Arch Dermatol       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.